La vendita allo scoperto per LifeMD dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di LifeMD. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

LifeMD (NASDAQ:LFMD) Azioni, Report sulle vendite allo scoperto

LIFEMD INC

LifeMD

LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

LifeMD Inc

LifeMD, Inc. - 8.875% Series A Cumulative Perpetual Preferred Stock

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) posted a loss for the first<a href="https://www.benzinga.com/quote/SRPT/earnings"> quarter on Tuesday</a>.
Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.
"In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion," said Doug Ingram, CEO of Sarepta Therapeutics.
Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion
Sarepta Therapeutics shares dipped 26.6% to close at $46.75 on Tuesday.
These analysts made changes to their price targets on Sarepta Therapeutics following earnings announcement.
<ul>
<li>Needham analyst Gil Blum maintained Sarepta Therapeutics with a Buy and lowered the price target from $183 to $125.</li>
<li>Morgan Stanley analyst Matthew Harrison maintained the stock with an Overweight rating and lowered the price target from $182 to $113.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained Sarepta Therapeutics with a Neutral and cut the price target from $75 to $40.</li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07092647/image-72-1024x611.png" alt="" class="wp-image-905670" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07092647/image-72-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07092647/image-72-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07092647/image-72-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07092647/image-72.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

SRPT

Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results

WIIM

VOYA

Voya Financial shares are trading higher after the company reported better-than-expected Q1 financial results.

CRUS

Cirrus Logic shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance with its midpoint above estimates. Also, Barclays raised its price target on the stock from $80 to $90.

Dayforce shares are trading lower. The company reported Q1 financial results.

MRCY

Mercury Systems shares are trading lower after the company reported a Q3 adjusted EPS miss.

KVYO

Klaviyo shares are trading higher after Piper Sandler and Barclays raised their respective price targets on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst John Hecht downgraded Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) from Buy to Hold and announced a $180 price target. Discover Financial shares closed at $188.12 on Tuesday. <a href="https://www.benzinga.com/quote/DFS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Philip Gibbs downgraded the rating for Materion Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) from Overweight to Sector Weight. Materion shares closed at $78.28 on Tuesday. <a href="https://www.benzinga.com/quote/MTRN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Lofting downgraded the rating for Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Neutral. Equinor shares closed at $23.27 on Tuesday. <a href="https://www.benzinga.com/quote/EQNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John McNulty downgraded Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) from Outperform to Market Perform and lowered the price target from $13 to $7. Tronox shares closed at $5.31 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst James Ricchiuti downgraded the rating for FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) from Buy to Hold and maintained the price target of $38. Faro Technologies shares closed at $42.36 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DFS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-1024x576.png" alt="" class="wp-image-905473" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

EQNR

FARO

MTRN

TROX

XENE

This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Charles River shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance.

Stephens &amp; Co. analyst Jim Salera maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight and lowers the price target from $24 to $23.

FWRG

Stephens & Co. Maintains Overweight on First Watch Restaurant Gr, Lowers Price Target to $23

ARDT

Ardent Health Partners shares are trading higher after the company reported better-than-expected Q1 EPS results.

FLYW

Flywire shares are trading higher after the company reported a year-over-year increase in Q1 EPS results and better-than-expected sales results.

Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 22.5 percent decrease over losses of $(0.40) per share from the same period last year.

Earnings Misses

BRNS

Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate

Theriva Biologics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its "reasonable best efforts" public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately and will expire five years from the issuance date.
The closing of the Offering is expected to occur on or about May 8, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this Offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. The Company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although it currently has no commitments or agreements with respect to any such investments or acquisitions.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.

Offerings

TOVX

Theriva Biologics Announces Pricing Of $7.5M Public Offering Of Up To 6,818,180 Shares Of Common Stock And Warrants To Purchase Up To 6,818,180 Shares Of Common Stock At A Combined Offering Price Of $1.10 Per Share And Accompanying Warrant

ODP shares are trading higher after the company reported better-than-expected Q1 financial results.

HRTG

Heritage Insurance Holdings shares are trading higher after the company reported better-than-expected Q1 EPS results.

Fiverr International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) reported <a href="https://www.benzinga.com/pressreleases/25/05/g45244008/fiverr-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> results on Wednesday. 
The company&#8217;s quarterly sales growth of 14.6% year-on-year to $107.2 million beat the analyst consensus estimate of $106.1 million. Fiverr also reported adjusted earnings per share of 64 cents, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of 59 cents.
As of March 31, there were 3.5 million active buyers versus 4 million last year. The spend per buyer rose 8.8% year over year to $309.
Also Read: <a href="https://www.benzinga.com/25/02/43813234/fiverr-q4-earnings-beats-estimates-projects-strong-2025-growth-ai-innovation-expands" target="_blank" rel="noreferrer noopener">Fiverr Beats Estimates In Q4, Projects AI-Powered Expansion And Rising Buyer Spend</a>
The marketplace take rate expanded by 20 bps to 27.7%.
The adjusted gross margin declined 50 basis points to 84.4%, while the adjusted EBITDA margin expanded 100 basis points to 18.1%.
The operating loss for the quarter was $(5.2) million, compared to a loss of $(4.2) million last year.
As of March 31, 2024, Fiverr generated $28.3 million in operating cash flow and held $502.1 million in cash and equivalents.
CEO Micha Kaufman attributed the quarterly results to stable Marketplace performance, robust Services revenue growth, and rapid AI product expansion. Following its Fiverr Go launch, the company noted positive signs on buyer conversion, with buyers converting more and faster, as well as making more quality purchase decisions.
Outlook: Fiverr expects second-quarter fiscal 2025 revenue of $105 million-$109 million, against the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst&nbsp;consensus estimate</a> of $94.7 million. Adjusted EBITDA of $20 million-$22 million.
Fiverr now expects fiscal 2025 revenue of $425 million-$438 million (<a target="_blank" href="https://www.benzinga.com/25/02/43813234/fiverr-q4-earnings-beats-estimates-projects-strong-2025-growth-ai-innovation-expands" rel="noreferrer noopener">prior $422 million–$438 million</a>)&nbsp;versus the&nbsp;analyst consensus estimate of $418.7 million. It now expects an adjusted EBITDA of $84 million-$90 million (prior $82 million–$90 million). The updated guidance reflects the company&#8217;s confidence and prudence in forecasting its business through a volatile macro environment.
Price Action: Fiverr stock is up 2.91% at $27.57 premarket at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45238222/teslas-future-hinges-on-china-fsd-analyst-says" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Future Hinges On China FSD: Goldman Sachs</a></li>
</ul>
Image: Shutterstock

Guidance

FVRR

Fiverr Beats Q1 Estimates On Strong Buyer Spend, AI Push, Lifts 2025 Revenue Outlook

Vicon Industries, a subsidiary of Cemtrex Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) and a leading provider of advanced security and surveillance solutions, today announced it has secured a significant new order valued at approximately $1 million from one of Saudi Arabia's leading media and broadcasting organizations. The order includes the company's latest innovation, the&nbsp;NEXT Modular Sensor System, and marks a major milestone for Vicon's expansion into the Gulf region.

CETX

Cemtrex's Vicon Industries Secures About $1M Order From Saudi Arabia's Major Media And Broadcasting Organization

LFMD

LifeMD shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.

Needham analyst Quinn Bolton maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and lowers the price target from $140 to $100.

ALAB

Needham Maintains Buy on Astera Labs, Lowers Price Target to $100

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $207 to $169.

BIIB

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $169

Press Releases

LifeMD Reports Fourth Quarter 2024 Results

Dividends

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference

Medifast to Announce Financial Results for the First Quarter Ended March 31, 2025

General

LifeMD Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs

LifeMD Acquires Women's Health Provider Optimal Human Health MD to Accelerate Entry into the Women's Health Market

LifeMD to Report First Quarter 2025 Financial Results on May 6

Medifast Announces First Quarter 2025 Financial Results

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

Comments

LifeMD

Vendite allo scoperto

LifeMD (NASDAQ:LFMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO